1. Home
  2. BRFH vs BTAI Comparison

BRFH vs BTAI Comparison

Compare BRFH & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Barfresh Food Group Inc.

BRFH

Barfresh Food Group Inc.

N/A

Current Price

$3.20

Market Cap

50.7M

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$2.10

Market Cap

49.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRFH
BTAI
Founded
2005
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.7M
49.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BRFH
BTAI
Price
$3.20
$2.10
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$6.00
$32.80
AVG Volume (30 Days)
6.3K
658.3K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$11,574,000.00
$752,000.00
Revenue This Year
$37.56
N/A
Revenue Next Year
$101.44
$544.99
P/E Ratio
N/A
N/A
Revenue Growth
17.49
N/A
52 Week Low
$2.00
$1.17
52 Week High
$6.08
$9.26

Technical Indicators

Market Signals
Indicator
BRFH
BTAI
Relative Strength Index (RSI) 48.61 51.76
Support Level $3.28 $1.82
Resistance Level $3.44 $2.33
Average True Range (ATR) 0.13 0.17
MACD 0.02 0.05
Stochastic Oscillator 39.39 62.87

Price Performance

Historical Comparison
BRFH
BTAI

About BRFH Barfresh Food Group Inc.

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: